First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
暂无分享,去创建一个
R. Whitbourn | P. Fitzgerald | A. Lansky | D. Kandzari | W. Wijns | M. Vrolix | J. Ormiston | M. Webster | J. Stewart | G. Attizzani | C. Knape | Dennis J. Donohoe
[1] C. Terkelsen,et al. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial , 2013, The Lancet.
[2] R. Ferrari,et al. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). , 2013, European heart journal.
[3] H. Bezerra,et al. Serial Evaluation of Vascular Response After Implantation of a New Sirolimus-Eluting Stent With Bioabsorbable Polymer (MISTENT): an optical coherence tomography and histopathological study. , 2012, The Journal of invasive cardiology.
[4] A. Tzafriri,et al. Enhanced drug delivery capabilities from stents coated with absorbable polymer and crystalline drug. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[5] Soo-Jin Kang,et al. In-stent neoatherosclerosis: a final common pathway of late stent failure. , 2012, Journal of the American College of Cardiology.
[6] P. Serruys,et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. , 2012, European heart journal.
[7] G. Stone,et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis , 2012, The Lancet.
[8] J. Ormiston,et al. Stent thrombosis: has the firestorm been extinguished? , 2012, The Lancet.
[9] C. Terkelsen,et al. Randomized Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients Treated With Percutaneous Coronary Intervention: The Scandinavian Organization for Randomized Trials With Clinical Outcome IV (SORT OUT IV) , 2012, Circulation.
[10] Y. Hayashi,et al. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry. , 2012, Circulation.
[11] F. Eberli,et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial , 2011, The Lancet.
[12] S. de Servi,et al. Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. , 2011, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[13] John A Ormiston,et al. Stent longitudinal integrity bench insights into a clinical problem. , 2011, JACC. Cardiovascular interventions.
[14] M. Leon,et al. Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents. , 2011, JACC. Cardiovascular interventions.
[15] T. Stijnen,et al. Clinical performance of drug-eluting stents with biodegradable polymeric coating: a meta-analysis and systematic review. , 2011, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[16] Gregg W Stone,et al. Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. , 2011, Journal of the American College of Cardiology.
[17] F. Eberli,et al. Five-Year Clinical and Angiographic Outcomes of a Randomized Comparison of Sirolimus-Eluting and Paclitaxel-Eluting Stents: Results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE Trial , 2011, Circulation.
[18] Masataka Nakano,et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. , 2011, Journal of the American College of Cardiology.
[19] R. Virmani,et al. Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents. , 2011, Journal of the American College of Cardiology.
[20] R. Virmani. Evolving DES Platforms , 2010 .
[21] P. Fitzgerald,et al. Six-Month Results of the NEVO RES-ELUTION I (NEVO RES-I) Trial: A Randomized, Multicenter Comparison of the NEVO Sirolimus-Eluting Coronary Stent With the TAXUS Liberté Paclitaxel-Eluting Stent in De Novo Native Coronary Artery Lesions , 2010, Circulation. Cardiovascular interventions.
[22] P. Smits,et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial , 2010, The Lancet.
[23] Xin-gang Wang,et al. Long-term effects of novel biodegradable, polymer-coated, sirolimus-eluting stents on neointimal formation in a porcine coronary model. , 2009, International heart journal.
[24] Patrick W Serruys,et al. Reproducibility of quantitative optical coherence tomography for stent analysis. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[25] F. Eberli,et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial , 2008, The Lancet.
[26] P. Fitzgerald,et al. Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients. , 2007, The American journal of cardiology.
[27] A. Kaltoft,et al. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. , 2007, Journal of the American College of Cardiology.
[28] R. Virmani,et al. Pathological Correlates of Late Drug-Eluting Stent Thrombosis: Strut Coverage as a Marker of Endothelialization , 2007, Circulation.
[29] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[30] Ralph D'Agostino,et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. , 2007, The New England journal of medicine.
[31] Michael Joner,et al. Drug-Eluting Stent and Coronary Thrombosis: Biological Mechanisms and Clinical Implications , 2007, Circulation.
[32] P. Fitzgerald,et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. , 2006, Journal of the American College of Cardiology.
[33] Patrick Hunziker,et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. , 2006, Journal of the American College of Cardiology.
[34] M. Briel,et al. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. , 2006, European heart journal.
[35] Matthew H Samore,et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. , 2006, Journal of the American College of Cardiology.
[36] C. Indolfi,et al. Drug-eluting stents versus bare metal stents in percutaneous coronary interventions (a meta-analysis). , 2005, The American journal of cardiology.
[37] G. Stone,et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. , 2004, The New England journal of medicine.
[38] E J Topol,et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. , 1990, Circulation.
[39] Giuseppe Biondi-Zoccai,et al. Examination of the in vivo mechanisms of late drug-eluting stent thrombosis: findings from optical coherence tomography and intravascular ultrasound imaging. , 2012, JACC. Cardiovascular interventions.
[40] B. Gersh. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial , 2009 .
[41] M. Pfisterer,et al. BASKET-LATE INVESTIGATORS, LATE CLINICAL EVENTS AFTER CLOPIDOGREL DISCONTINUATION MAY LIMIT THE BENEFIT OF DRUGELUTING STENTS: AN OBSERVATIONAL STUDY OF DRUG-ELUTING VERSUS BARE-METAL STENTS , 2006 .
[42] Ousa,et al. A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION , 2002 .